

# Using Machine Learning to Predict the Risk of Either Having an Aggressive Form of Prostate Cancer (PCa) or Lower Grade PCa/Benign Prostatic Hyperplasia (BPH) Based Upon the Flow Cytometry Immunophenotyping of Myeloid-derived Suppressor Cells (MDSCs) and Lymphocyte Cell Populations

George A. Dominguez<sup>1</sup>, John Roop<sup>1</sup>, Alexander Polo<sup>1</sup>, Anthony Campisi<sup>1</sup>, Dmitry I. Gabrilovich<sup>2</sup>, and Amit Kumar<sup>1</sup>

<sup>1</sup>Anixa Biosciences, Inc., San Jose, CA; <sup>2</sup>The Wistar Institute, Philadelphia, PA


# Flow Cytometry Based Immunophenotyping

## Flow Cytometry

- ✓ 50+ years in use
- ✓ A foundation of immunology and tumor immunology research
- ✓ Real time analysis for thousands of cells per second
- ✓ Multiple cell markers can be used
- ✓ Cost Effective


## Immunophenotyping

- ✓ Know what you are looking for
- ✓ Manual gating = Boolean logic
- ✓ Operator experience
- ✓ More parameters (N) = more 2D unique relationships (R)
  - ✓  $N = 2$ ;  $R = 1$
  - ✓  $N = 3$ ;  $R = 3$
  - ✓  $N = 4$ ;  $R = 6$
  - ✓  $N = 5$ ;  $R = 10$
- ✓ Higher dimensions difficult for us to understand





# Myeloid-derived Suppressor Cells – What about them?





## Indicative of Solid Tumors and Severity



## Predictors of Immunotherapy Response?



## CTLA-4 Responses in Late Stage Melanoma




# First Question

---


Can we use MDSCs and other leukocytes as a predictor for higher grade prostate cancer (PCa) and distinguish them from benign prostatic hyperplasia (BPH)/lower grade PCa?

# Myeloid and Lymphocyte Immunophenotyping


## Myeloid Panel (10 Markers)



## Lymphoid Panel (5 Markers)



# Traditional Gating: Manual Counting - MDSCs



***Simple cell counts can provide information about trends, but can only categorize some subjects***

Healthy Donor (HD) n = 73

Benign Prostatic Hyperplasia (BPH) n = 48


Prostate Cancer (PCa) n = 73

\*The dotted line represents the 75<sup>th</sup> percentile for HD values (75% specificity)




## Next Question

Can we use machine learning (neural networks) to analyze the flow cytometry data to categorize patients?




# Neural Network – A Type of AI









# Complex Relationships – More Than Just Gating







# Complex Relationships – More Than Just Gating

Myeloid  
Panel




Lymphocyte  
Panel




# Data Transformation

FCS File → CSV File (Event counts for each channel)



## Multidimensional Space




How do we effectively translate the flow cytometry data into a format for NN analysis?




# Data Transformation – What is the Common Feature?

- Samples to be used by a neural network must have features in common across all samples
- For images, every sample has some specific pixel value for each pixel space
  - The pixels are the common features across all images
- But there is no common feature *for the entire sample set* in flow cytometry data
  - An immunofluorescence channel value on a specific event is a common feature across all cells, not between samples




# Hypervoxel Generation – The Inputs

## 2D: Pixel




## 3D: Voxel



# Hypervoxel Generation – The Inputs

## Multidimensions (>3D): Hypervoxel



8 Markers  
+  
DAPI

$4^9 = 262,144$   
Unique Hypervoxel Spaces

## What is the input for the network?


- Each hypervoxel is a unique address
- Each event has channel values that give it an address to a hypervoxel
- The number of events that fall into that address is counted to be the input to the network
  - array of counts

## Dataset Generation

- 100,000 events are collected per sample
- Create sibling samples – variations of 50,000 events
- Per sample – 20 sibling samples are created






# Neural Network – Binary Classifier



# Clinical Characteristics and Manual Counting

Characteristic	PCa	BPH
Total	145	115
Median Age	68	63
Age Range	42 – 86	40 – 81
Gleason Score		
6	55	
7 (3+4)	31	
7 (4+3)	31	
>8	28	
T-Stage (AJCC 8 <sup>th</sup> Ed.)		
T1c	117	
T2a	6	
T2c	1	
Unknown	21	



***Still...simple cell counts can provide information about trends, but not really categorize subjects***

# Clinical Application: Confirmatory Testing

		Actual	
		HR-PCa	BPH/LR-PCa
Test	HR-PCa	46	33
	BPH/LR-PCa	3	24
Sens. (%) (95%CI)		93.88	(83.13 to 98.72)
Spec. (%) (95%CI)		42.11	(29.14 to 55.92)
PPV (%) (95%CI)		58.23	(52.48 to 63.76)
NPV (%) (95%CI)		88.89	(71.94 to 96.15)
Acc. (%) (95%CI)		66.04	(56.20 to 74.96)

Population: Men who were going to prostate biopsy

Samples used for training:

41 HR-PCa  
113 BPH/LR-PCa

Holdout Samples for Testing:

49 HR-PCa  
57 BPH/LR-PCa

➤ Potentially reduce the number of unnecessary prostate biopsies?

# Conclusions

---

- We demonstrated that we can combine machine learning with flow cytometry data
  - Pros: Objective, Large Amounts of Data, More Data Inclusion, Simple Assay
  - Cons: Supervised Learning, Requires Large Amounts of Data for Training, Difficult to Determine Most Important Relationship – “Black Box” Idea
- We have applied this technique to be a binary classifier
  - distinguish between BPH/PCa in a small number of samples
- This can be used for other classifications and tumor types
  - Breast Cancer: Early Stage vs non-Tumor Bearing
  - Breast Cancer: Early Stage vs DCIS
  - Prostate Cancer: Advanced Stage vs non-Tumor Bearing

# Future Work

---

- Identify the critical relationships between cell populations that are used to make the classifications → hypervoxels
- Can this technique be applied to other flow cytometry data sets with different cancers or more cell populations? CyTOF? (retrospective analysis)
- As more and more data sets are generated with more and more information, can this help answer the question: What do we do with all of this data? What are we really trying to answer?
- Can this be used for answering other questions?
  - tumor recurrence, treatment and/or immunotherapy responses
    - Collaborative projects

# Thank You!

---

## **Anixa Biosciences**

*San Jose*                      *Philadelphia*  
Amit Kumar, PhD      Alexander Polo  
John Roop  
Anthony Campisi

## **The Wistar Institute**

Dmitry I. Gabrilovich, MD, PhD  
Flow Cytometry Core Facility  
Jeffrey Faust

## **Clinical Collaborators**

*New Jersey Urology, LLC*  
Adam Perzin, MD  
Renee Haney, CCRC  
Brianna Florentine, CRC  
Jennifer Pilallis, CRC

*MD Anderson Cancer Center at Cooper*  
Robert Somer, MD  
Mary Schafer



---

# Questions?